Current Report · Items 5.02, 9.01 · 8-K

Cannabist Co Holdings Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Apr 7, 2026Accepted Apr 7, 2026, 9:03 AM EDTCIK 1776738Accession 0001140361-26-013501

Company context

The Cannabist Company, formerly known as Columbia Care, owns subsidiaries that are cultivators, manufacturers and providers of cannabis products and related services, with licenses in 10 U.S. jurisdictions. The Company’s subsidiaries operate 58 facilities including 43 dispensaries and 15 cultivation and manufacturing facilities, including those facilities subject to pending sale or wind-down. Founded as Columbia Care, with a focus on medical applications of cannabis and emphasis on institutional research and clinical outcomes, the Company is one of the original multi-state providers of cannabis in the U.S. and now delivers products and services to both the medical and adult-use markets. In 2021, in response to the proliferation of adult use markets, the Company launched Cannabist, its retail brand, creating a national dispensary network through its subsidiaries. The Company’s subsidiaries offer products spanning flower, edibles, oils and tablets, and manufactures popular brands including dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit www.cannabistcompany.com.

Current securities

CBSTQOTC · EQUITY · Current

Historical securities (1)

CBSTNEO · EQUITY · Historical · closed Jun 18, 2026

Recent company filings

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2026, Jesse Channon, the President of The Cannabist Company Holdings Inc. (the “Company”), resigned his employment position with the Company, effective April 1, 2026. In connection with his resignation, the Company and Mr. Channon entered into a Consulting Engagement Agreement, dated April 1, 2026 (the “Consulting Agreement”), as further described below. Through the Consulting Agreement, Mr. Channon will provide certain corporate services to the Company in a non-employee consultant capacity. Mr. Channon joined the Company as an employee in 2019 as the Chief Growth Officer prior to becoming its Chief Commercial Officer and then President. Pursuant to the Consulting Agreement, the Company will pay Mr. Channon $10,000 per month. The initial term of the Consulting Agreement is from April 2, 2026, to July 3, 2026, and may continue until modified or terminated on its terms. The Consulting Agreement also contains customary confidentiality provisions. The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, which is filed as an Exhibit 10.1 hereto.